Clinuvel Pharmaceuticals
Sells afamelanotide (Scenesse) for erythropoietic protoporphyria and is testing it in vitiligo.
Share price
7.94 AUD
What analysts expect
Buy
Buy55%
Hold45%
Sell0%
Price target for the next 12 months
17.40 AUDUp 133% compared with the current price
Price now 7.46 AUDAverage targetLowest 9.52 AUD to highest 39.30 AUD
7 analysts. One high target of about AUD 39 pulls the average up. Source: MarketScreener, 20 Oct 2026. Targets are opinions and are often wrong.
Business
- Yearly revenue
- 96M AUD
- Yearly profit
- 33M AUD
- Company value
- 412M AUD
Revenue and profit for the last twelve months reported.
Peptides in this book
- AfamelanotidePrescription
Recent news
Risk in the news: RTTNews reported that fiscal 2026 profit fell about 6 percent and the shares declined.
Prices are delayed and figures rounded. Not investment advice.